The efficacy and safety of infliximab in patients with ankylosing spondylitis: results of an open-labeled multicenter study

  • Authors: Bunchuk N.V.1, Rumyantseva O.A.1, Loginova E.Y.1, Bochkova A.G.1, Storozhakov G.I.1, Ettinger O.A.1, Kosyura S.D.1, Kamalova R.G.1, Valishina LM1, Bunchuk NV1, Rumyantseva OA1, Loginova EY.1, Bochkova AG1, Storozhakov GI1, Ettinger OA1, Kosyura SD1, Kamalova RG1, Valishina LM1
  • Affiliations:
  • Issue: Vol 82, No 10 (2010)
  • Pages: 41-46
  • Section: Editorial
  • URL:
  • Cite item


Aim. To evaluate the efficacy and tolerability of the anti-tumor necrosis factor-α infliximab in patients with active ankylosing spondylitis (AS) in a 54-week multicenter open-label study.
Subjects and methods. The study enrolled 42 patients with AS who continued to have an active phase of the disease despite that they had received standard therapy. All but one patient had signs of active spondylitis; peripheral arthritis was noted in 52%; enthesitis was seen in 79%. Infliximab was administered in a dose of 5 mg/kg as 2-hour intravenous infusions; the second and third infusions were injected 2 and 6 weeks after the first one; all further infusions were used at an interval of 6-8 weeks.
Results. Thirty-three (78.6%) of the 42 patients completed the trial. There was a considerable, at least 50%, improvement in the ASAS criteria in 84.8% of the patients who completed the trial. A substantial therapeutic effect was observed in the majority of patients just a week after the first infusion of infliximab. There was a statistically improvement in all the analyzed clinical effectiveness indicators, including the Bath AS Disease Activity Index (BASDAI); pain became less in the vertebral column and joints (on an average from 49.6 to 12.4 mm on the 100-mm visual analog scale); the level of C-reactive protein and the number of swollen and tender entheses were decreased. The patients' functional capacity improved considerably (the Bath AS Functional index (BASFI) decreased on average from 59.7 to 16.3 scores). Nine (21.4%) patients were withdrawn from the study ahead of time: 7 and 2 patients because of adverse reactions (AR) and contact loss, respectively. The most common ARs were airway infections (13.6%), hepatic dysfunction (12.0%), and herpes simplex virus infections (10.4%). Four patients developed the severest ARs (pulmonary tuberculosis, generalized psoriasis-like dermatitis, pneumonia, and abscess of the epithelial coccygeal tract); the outcome of all complications was good.
Conclusion. The results of the study suggest that infliximab has a high, rapidly occurring and stably preserving efficiency in most patients with active AS. The frequency and spectrum of ARs corresponded to the available data on the tolerability of infliximab.

About the authors

Nikolay Vasil'evich Bunchuk


Oksana Alekseevna Rumyantseva


Elena Yur'evna Loginova


Anna Georgievna Bochkova


Gennadiy Ivanovich Storozhakov

Ol'ga Aleksandrovna Ettinger

Svetlana Dmitrievna Kosyura

Rimma Galimovna Kamalova


L M Valishina

N V Bunchuk

O A Rumyantseva

E Yu Loginova

A G Bochkova

G I Storozhakov

O A Ettinger

S D Kosyura

R G Kamalova

L M Valishina


  1. Фоломеева О. М., Эрдес Ш. Ревматические заболевания у взрослого населения в федеральных округах Российской Федерации. Науч. практ. ревматол. 2006; 2: 4-9.
  2. Braun J., Brandt J., Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
  3. Van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthr. and Rheum. 2005; 52: 582-591.
  4. Maksymowych W., Jhangri G., Lambert R. et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J. Rheumatol. 2002; 29: 259-265.
  5. Nikas S., Alamanos Y., Voulgari P. et al. Infliximab therapy in ankylosing spondylitis: an observational study. Ann. Rheum. Dis. 2005; 64: 940-942.
  6. Braun J., Baraliakos X., Listing J. et al. Persistent clinical efficacy and safety of anti-TNF-α therapy with infliximab in patients with ankylosing spondylitis over 5 years - evidence for different types of response. Ann. Rheum. Dis. 2008; 67: 340- 345.
  7. Румянцева О. А., Кузин А. В., Бунчук Н. В. Применение ремикейда при анкилозирующем спондилоартрите. Предварительные результаты. Клин. фармакол. и фармакотер. 2004; 13 (1): 89-93.
  8. Румянцева О. А., Бочкова А. Г., Логинова Е. Ю. и др. Исследование эффективности, безопасности и переносимости инфликсимаба у больных анкилозирующим спондилитом (предварительные результаты). Науч.-практ. ревматол. 2006; 4: 11-20.
  9. Van der Linden S., Valkenburg H., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr. and Rheum. 1984; 27: 361-368.
  10. Anderson J., Baron G., van der Heijde D. et al. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthr. and Rheum. 2001: 44: 1876-1886.
  11. Braun J., Brandt J., Listing J. et al. Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthr. and Rheum. 2003; 48: 2224-2233.
  12. Breban M., Ravaud P., Claudepierre P. et al. Maintenance of infliximab treatment in ankylosing spondylitis results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthr. and Rheum. 2008; 58: 88-97.
  13. de Vries M., Wolbink G., Stapel S. et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann. Rheum. Dis. 2007; 66: 1252- 1254.
  14. van den Bosch F., Devinck M., Kruithof E. et al. 5-year safety and efficacy follow-up in 107 spondyloarthropathy patients with continued long-term infliximab treatment. Ann. Rheum. Dis. 2005; 64 (Suppl. 3): 1079.
  15. Remicade (infliximabe) current (May 2007) prescribing information. http://www.
  16. Dixon W., Lunt W., Hyrich K. et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthr. and Rheum. 2006; 54: 2368-2376.
  17. Beglinger C., Dudler J., Mottet C. et al. Screening for tuberculosis infection before initiation of anti-TNF-α-therapy. Swiss Med. Wkly 2007; 137: 621-622.
  18. Collamer A., Guerrero K., Henning J., Battafarano D. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthr. and Rheum. 2008; 59: 996-1001.
  19. Landewe R., Rump B., van der Heijde D., van der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann. Rheum. Dis. 2004; 63: 530-534.
  20. Cruyssen B., Ribbens C., Boonen A. et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann. Rheum. 2007; 66: 1072-1077.
  21. Dawes P., Packham J., Mucklow J. TNF therapy for spondyloarthropathy: can we marshal the argument? Rheumatology 2004; 43: 1069-1071.



Abstract - 55



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies